Key facts
- This page summarizes Timothy J. Barberich's Form 4 filing for TScan Therapeutics, Inc. (TCRX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Dec 2023, 17:00.
Timothy J. Barberich - 18 Dec 2023 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)
- Reporting relationship
- Director
- Issuer ticker
- TCRX
- Reported as of
- 18 Dec 2023
- Net transaction value
- +$142,456
- SEC form
- 4
- Accepted by SEC
- 21 Dec 2023, 17:00:47 UTC
- Prior SEC filing
- 15 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Timothy Barberich
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Timothy J. Barberich filed Form 4 for TScan Therapeutics, Inc. (TCRX) on 21 Dec 2023.
Change
- Previous filing in this sequence was filed on 15 Jun 2023.
- Current net transaction value: +$142,456.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TCRX
transaction
Voting Common Stock
Purchase
- Transaction value
- $140,881
- Shares
- +28,830
- Change %
- +76%
- Price
- $4.89
- Shares after
- 66,710
- Date
- 18 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
TCRX
transaction
Voting Common Stock
Purchase
- Transaction value
- $1,575
- Shares
- +317
- Change %
- +0.48%
- Price
- $4.97
- Shares after
- 67,027
- Date
- 19 Dec 2023
- Ownership
- Direct
TCRX
holding
Voting Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 33,259
- Date
- 18 Dec 2023
- Ownership
- By Barberich Family Trust
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $4.63 to $5.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
Footnote F2
These shares are held in a trust for the benefit of the Reporting Person's children. The Reporting Person's spouse is the grantor of the trust and retains certain rights to remove and replace the trustee of the trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.